CorMedix Inc. (CRMD) reported 384.60% year-over-year revenue growth on June 17, 2026. This performance distinguishes the company among its small-cap healthcare peers.
Strong market demand for the flagship product DefenCath drove the substantial increase. The biopharmaceutical company focuses on commercializing therapeutic products for life-threatening diseases.
CorMedix raised its full-year 2026 guidance following strong first-quarter results. These developments signal sustained business momentum within the biotechnology sector.